Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 16NET 15CNS 6Gastrointestinal 5Genitourinary 2Sarcoma 1Other neoplasm 1Dermatologic 1

Conditions

Digestive System Neuroendocrine Tumor G1 1

Interventions

Magnetic Resonance Spectroscopy 3Biopsy 3fludarabine 2Taxes 2Paclitaxel 2Endoscopic Mucosal Resection 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2venetoclax 1trametinib 1toripalimab 1thymoglobulin 1taxane 1sintilimab 1potassium oxonate 1lutetium Lu 177 dotatate 1gimeracil 1fludarabine phosphate 1dabrafenib 1apatinib 1Whole-Body Irradiation 1Watchful Waiting 1Transurethral Resection of Prostate 1Tegafur 1Surgical Procedures, Operative 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × lutetium Lu 177 dotatate × Other neoplasm × Clear all
NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt-Ingram Cancer Center

Phase 4 Recruiting
6 enrolled
EndocrineGastrointestinalNETOther neoplasm

Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡